DSR-6434 stimulates TLR7 activity only in HEK293 cells expressing hTLR7 and not in HEK293 cells expressing the structurally similar hTLR8 or hTLR9. The successful binding of DSR-6434 to the specific receptor leads to NF-Κb activation[1].

DSR-6434 is a selective agonist of TLR7 with antitumor effect. DSR-6434 exhibits EC50s of 7.2 nM and 4.6 nM for human and mouse.

To assess the specificity of DSR-6434 toward TLR7, an NF-κB-driven reporter assay is performed in HEK293 cells engineered to express either hTLR7, TLR8 or TLR9. In this assay, successful binding of DSR-6434 to the specific receptor leads to NF-κB activation. DSR-6434 is capable of stimulating reporter gene activity only in HEK293 cells expressing hTLR7 and not in HEK293 cells expressing the structurally similar hTLR8 or hTLR9[1].

In B6C3F1 mice, DSR-6434 (0.1-1 mg/kg; i.v.) significantly suppresses lung metastasis[1].

1059070-10-8

C19H28N8O2

400.48

DMSO:225mg/mL (561.8mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years